| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0962280217748339 |
| P698 | PubMed publication ID | 29278143 |
| P50 | author | Jos Bloemers | Q57025496 |
| Rob Kessels | Q89734529 | ||
| P2093 | author name string | Reagan Mozer | |
| P2860 | cites work | The Hawthorne Effect: a randomised, controlled trial | Q21261930 |
| Concept of true and perceived placebo effects | Q24645411 | ||
| Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome | Q24647883 | ||
| A New Design for Randomized Clinical Trials | Q28239541 | ||
| Estimating causal effects of treatments in randomized and nonrandomized studies. | Q29012064 | ||
| The quantification of placebo effects within a general model of health care outcomes | Q30425176 | ||
| Biological, clinical, and ethical advances of placebo effects | Q33703954 | ||
| Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology | Q33886704 | ||
| Novel study designs to investigate the placebo response | Q33929541 | ||
| Latent Regression Analysis | Q33962271 | ||
| The powerful placebo | Q33969075 | ||
| Principal stratification in causal inference | Q34065063 | ||
| Placebo response in studies of major depression: variable, substantial, and growing | Q34122652 | ||
| Group analysis versus individual response: the inferential limits of randomized controlled trials | Q34192035 | ||
| Prediction of placebo responses: a systematic review of the literature | Q34272476 | ||
| Optimal Partitioning for Linear Mixed Effects Models: Applications to Identifying Placebo Responders. | Q34428698 | ||
| Placebo response in antipsychotic clinical trials: a meta-analysis | Q34443837 | ||
| The double-blind variable placebo lead-in period: results from two antidepressant clinical trials | Q34474851 | ||
| Increasing placebo responses over time in U.S. clinical trials of neuropathic pain | Q34491005 | ||
| The nature and power of the placebo effect | Q34503638 | ||
| Identifying differential responders and their characteristics in clinical trials: innovative methods for analyzing longitudinal data | Q34556381 | ||
| Using the Zelen design in randomized controlled trials: debates and controversies. | Q34592360 | ||
| A comprehensive review of the placebo effect: recent advances and current thought | Q34634630 | ||
| What are the main methodological problems in the estimation of placebo effects? | Q34635532 | ||
| Do "placebo responders" exist? | Q34766089 | ||
| Identification of Multivariate Responders/Non-Responders Using Bayesian Growth Curve Latent Class Models | Q35014266 | ||
| The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach | Q35111772 | ||
| Individual response to treatment: is it a valid assumption? | Q35925122 | ||
| A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response | Q36059902 | ||
| A model of placebo response in antidepressant clinical trials | Q36774011 | ||
| Bayesian multivariate growth curve latent class models for mixed outcomes | Q36912551 | ||
| Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial | Q37019876 | ||
| Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain | Q37079409 | ||
| Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder | Q37338715 | ||
| Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
| The placebo response in clinical trials: more questions than answers | Q37876002 | ||
| The placebo response in medicine: minimize, maximize or personalize? | Q38085499 | ||
| Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials | Q38410482 | ||
| Mechanisms of the placebo effect in pain and psychiatric disorders | Q38784077 | ||
| Unsolved, Forgotten, and Ignored Features of the Placebo Response in Medicine | Q39029789 | ||
| Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. | Q39375980 | ||
| Assessing placebo response using Bayesian hierarchical survival models | Q40861081 | ||
| Principal Point Classification: Applications to Differentiating Drug and Placebo Responses in Longitudinal Studies. | Q41066154 | ||
| Placebo non-response measure in sequential parallel comparison design studies | Q41086057 | ||
| Use of pattern analysis to identify true drug response. A replication | Q41453243 | ||
| Estimation of treatment effect for the sequential parallel design | Q41854511 | ||
| Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling | Q41874724 | ||
| A causal model for joint evaluation of placebo and treatment-specific effects in clinical trials | Q41900452 | ||
| Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials | Q42379485 | ||
| Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. | Q42609298 | ||
| A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trials | Q43581769 | ||
| Estimating probability of non-response to treatment using mixture distributions | Q43640582 | ||
| A typological model for estimation of drug and placebo effects in depression | Q44097685 | ||
| A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal | Q44216589 | ||
| Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse | Q44784143 | ||
| A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies | Q45360532 | ||
| A New Population-Enrichment Strategy to Improve Efficiency of Placebo-Controlled Clinical Trials of Antidepressant Drugs | Q45916380 | ||
| Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. | Q46021497 | ||
| Finite mixture modeling with mixture outcomes using the EM algorithm | Q46119501 | ||
| General growth mixture modeling for randomized preventive interventions. | Q46346093 | ||
| Hidden administration of drugs | Q46714765 | ||
| Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials | Q46791789 | ||
| Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials | Q46808078 | ||
| Adjusting for perception and unmasking effects in longitudinal clinical trials. | Q51598632 | ||
| Predicting potential placebo effect in drug treated subjects. | Q51873749 | ||
| An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. | Q51899544 | ||
| The ethics of Zelen consent. | Q53343343 | ||
| Statistics and Causal Inference | Q56070162 | ||
| Two-week delay in onset of action of antidepressants: new evidence | Q58809506 | ||
| P433 | issue | 4 | |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 1141-1156 | |
| P577 | publication date | 2017-12-26 | |
| P1433 | published in | Statistical Methods in Medical Research | Q7604374 |
| P1476 | title | Methods for assessing and controlling placebo effects | |
| P478 | volume | 28 |
Search more.